NCT02750553View on ClinicalTrials.gov

A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2016

Conditions
Healthy
Interventions
DRUG

SHR0534

DRUG

Placebo

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02750553 - A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter